Akut Myeloid Lösemi (AML) Tedavisinde Hedef Tedavilerde Yeni Gelişmeler Var mı?

Are there any new developments in targeted therapies for the treatment of Acute Myeloid Leukemia (AML)? 🧬 AML is a leukemia that starts rapidly and progresses aggressively. Treatment is three-step: 1️⃣ Induction (intensive chemotherapy) 2️⃣ Consolidation 3️⃣ Maintenance (in selected patients) 💊 What are the new targeted therapies? 🔹 Azacitidine + Venetoclax → Especially in patients who cannot tolerate intensive chemotherapy → Venetoclax targets BCL-2 (poptosis increased) 🔹 FLT3 inhibitors • Midostaurin (first-line) • Gilteritinib (relapsed/resistant) • Quizartinib, Sorafenib 🔹 IDH1/2 targeted therapies • Ivosidenib, Olutasidenib (IDH1) • Enasidenib (IDH2) 🔹 CD33 targeted therapy • Gemtuzumab ozogamicin 🧪 Next generation: • Menin inhibitors (Revumenib) → Promising in KMT2A / NPM1 mutations 📌 Conclusion: Instead of a single type of chemotherapy in AML, ➡️ mutation-specific, personalized therapies are now at the forefront. Are There New Targeted Therapies in AML? 🧬 AML is an aggressive leukemia. Treatment includes: 1️⃣ Induction 2️⃣ Consolidation 3️⃣ Maintenance (selected patients) 💊 Key targeted therapies: 🔹 Azacitidine + Venetoclax → For unfit patients → Targets BCL-2 🔹 FLT3 inhibitors • Midostaurin (frontline) • Gilteritinib (relapsed/refractory) 🔹 IDH inhibitors • Ivosidenib, Olutasidenib (IDH1) • Enasidenib (IDH2) 🔹 CD33-targeted therapy • Gemtuzumab ozogamicin 🧪 Emerging class: • Menin inhibitors (Revumenib) for KMT2A/NPM1 mutations 📌 AML care is shifting towards ➡️ precision, mutation-driven therapy rather than one-size-fits-all Chemotherapy. #profdrhakanismailsarı #hematologyistanbul #acutemyeloidleukemia #leukemia #leukemiatreatment #aml #whatisthetreatment